325 related articles for article (PubMed ID: 33176437)
21. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
[TBL] [Abstract][Full Text] [Related]
22. Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management.
Patel PH; Nguyen M; Rodriguez R; Surani S; Udeani G
Cureus; 2021 Jan; 13(1):e12419. PubMed ID: 33542867
[TBL] [Abstract][Full Text] [Related]
23. [CLINICAL EFFICACY OF A REPRESENTATIVE OF A NEW CLASS OF INOTROPIC AGENTS - THE DIRECT ACTIVATOR OF MYOSIN OF CARDIOMYOCYTES OMECAMTIV MECARBIL IN HEART FAILURE WITH A REDUCED EJECTION FRACTION].
Kravchenko I; Rudyk I; Medentseva O
Georgian Med News; 2021 Sep; (318):165-171. PubMed ID: 34628401
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF.
Selvaraj S; Claggett B; Pozzi A; McMurray JJV; Jhund PS; Packer M; Desai AS; Lewis EF; Vaduganathan M; Lefkowitz MP; Rouleau JL; Shi VC; Zile MR; Swedberg K; Solomon SD
Circulation; 2019 Oct; 140(17):1369-1379. PubMed ID: 31510768
[TBL] [Abstract][Full Text] [Related]
25. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
[TBL] [Abstract][Full Text] [Related]
26. Effects of the cardiac myosin activator Omecamtiv-mecarbil on severe chronic aortic regurgitation in Wistar rats.
El-Oumeiri B; Mc Entee K; Annoni F; Herpain A; Vanden Eynden F; Jespers P; Van Nooten G; van de Borne P
BMC Cardiovasc Disord; 2018 May; 18(1):99. PubMed ID: 29783950
[TBL] [Abstract][Full Text] [Related]
27. Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries.
Johansson I; Joseph P; Balasubramanian K; McMurray JJV; Lund LH; Ezekowitz JA; Kamath D; Alhabib K; Bayes-Genis A; Budaj A; Dans ALL; Dzudie A; Probstfield JL; Fox KAA; Karaye KM; Makubi A; Fukakusa B; Teo K; Temizhan A; Wittlinger T; Maggioni AP; Lanas F; Lopez-Jaramillo P; Silva-Cardoso J; Sliwa K; Dokainish H; Grinvalds A; McCready T; Yusuf S;
Circulation; 2021 Jun; 143(22):2129-2142. PubMed ID: 33906372
[TBL] [Abstract][Full Text] [Related]
28. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
Psotka MA; Teerlink JR
Handb Exp Pharmacol; 2017; 243():465-490. PubMed ID: 28315072
[TBL] [Abstract][Full Text] [Related]
29. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
Kosiborod MN; Verma S; Borlaug BA; Butler J; Davies MJ; Jon Jensen T; Rasmussen S; Erlang Marstrand P; Petrie MC; Shah SJ; Ito H; Schou M; Melenovský V; Abhayaratna W; Kitzman DW;
Circulation; 2024 Jan; 149(3):204-216. PubMed ID: 37952180
[TBL] [Abstract][Full Text] [Related]
30. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
Teerlink JR; Clarke CP; Saikali KG; Lee JH; Chen MM; Escandon RD; Elliott L; Bee R; Habibzadeh MR; Goldman JH; Schiller NB; Malik FI; Wolff AA
Lancet; 2011 Aug; 378(9792):667-75. PubMed ID: 21856480
[TBL] [Abstract][Full Text] [Related]
31. Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
Solomon SD; Claggett BL; Miao ZM; Diaz R; Felker GM; McMurray JJV; Metra M; Corbalan R; Filippatos G; Goudev AR; Mareev V; Serpytis P; Suter T; Yilmaz MB; Zannad F; Kupfer S; Heitner SB; Malik FI; Teerlink JR
Eur Heart J; 2022 Jun; 43(23):2212-2220. PubMed ID: 35325102
[TBL] [Abstract][Full Text] [Related]
32. Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER Trial.
Peikert A; Chandra A; Kosiborod MN; Claggett BL; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Janssens SP; Belohlávek J; Borleffs CJW; Dobreanu D; Langkilde AM; Bengtsson O; Petersson M; McMurray JJV; Solomon SD; Vaduganathan M
JAMA Cardiol; 2023 Jul; 8(7):684-690. PubMed ID: 37208998
[TBL] [Abstract][Full Text] [Related]
33. Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF.
Lewis GD; Docherty KF; Voors AA; Cohen-Solal A; Metra M; Whellan DJ; Ezekowitz JA; Ponikowski P; Böhm M; Teerlink JR; Heitner SB; Kupfer S; Malik FI; Meng L; Felker GM
Circ Heart Fail; 2022 May; 15(5):e008970. PubMed ID: 35236099
[TBL] [Abstract][Full Text] [Related]
34. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF.
Lanfear DE; Njoroge JN; Adams KF; Anand I; Fang JC; Ramires F; Sliwa-Hahnle K; Badat A; Burgess L; Gorodeski EZ; Williams C; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon S; Miao ZM; Claggett BL; Heitner SB; Kupfer S; Malik FI; Teerlink JR
JACC Heart Fail; 2023 May; 11(5):569-579. PubMed ID: 36881396
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.
Vu T; Ma P; Xiao JJ; Wang YM; Malik FI; Chow AT
J Clin Pharmacol; 2015 Nov; 55(11):1236-47. PubMed ID: 25951506
[TBL] [Abstract][Full Text] [Related]
36. Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction.
Adamo M; Metra M; Claggett BL; Miao ZM; Diaz R; Felker GM; McMurray JJV; Solomon SD; Biering-Sørensen T; Divanji PH; Heitner SB; Kupfer S; Malik FI; Teerlink JR;
JACC Heart Fail; 2024 Mar; 12(3):552-563. PubMed ID: 38300212
[TBL] [Abstract][Full Text] [Related]
37. Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil.
Kaplinsky E; Mallarkey G
Drugs Context; 2018; 7():212518. PubMed ID: 29707029
[TBL] [Abstract][Full Text] [Related]
38. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
Berg DD; Docherty KF; Sattar N; Jarolim P; Welsh P; Jhund PS; Anand IS; Chopra V; de Boer RA; Kosiborod MN; Nicolau JC; O'Meara E; Schou M; Hammarstedt A; Langkilde AM; Lindholm D; Sjöstrand M; McMurray JJV; Sabatine MS; Morrow DA
Circulation; 2022 Jan; 145(3):158-169. PubMed ID: 34743554
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF.
Docherty KF; McMurray JJV; Diaz R; Felker GM; Metra M; Solomon SD; Adams KF; Böhm M; Brinkley DM; Echeverria LE; Goudev AR; Howlett JG; Lund M; Ponikowski P; Yilmaz MB; Zannad F; Claggett BL; Miao ZM; Abbasi SA; Divanji P; Heitner SB; Kupfer S; Malik FI; Teerlink JR
J Card Fail; 2024 Jan; 30(1):26-35. PubMed ID: 37683911
[TBL] [Abstract][Full Text] [Related]
40. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study.
Givertz MM; Anstrom KJ; Redfield MM; Deswal A; Haddad H; Butler J; Tang WH; Dunlap ME; LeWinter MM; Mann DL; Felker GM; O'Connor CM; Goldsmith SR; Ofili EO; Saltzberg MT; Margulies KB; Cappola TP; Konstam MA; Semigran MJ; McNulty SE; Lee KL; Shah MR; Hernandez AF;
Circulation; 2015 May; 131(20):1763-71. PubMed ID: 25986447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
